It was instrumental in identifying potential MTDLs targeting the epidermal growth factor receptor (EGFR) and ALK tyrosine kinase receptor (ALK) in non-small-cell lung cancer (NSLC), as well as pan-agonists for dopamine receptors (DRD1–DRD5) for the treatment of neurodegenerative diseases. This evidence concerns the gene ALK and non-small cell lung carcinoma.